CMS SRT Reimbursement Tailwinds and Q3 Upside for SRTS in 2026
Aug 13, 2026, 4:29 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Catalysts include a likely Q3 revenue uplift from eight units previously deferred, plus a meaningful CMS code increase proposal that could improve hospital economics and accelerate adoption. Margin implications depend on mix; however, reimbursement tailwinds and international expansion could unlock faster top-line growth, supporting a positive price reaction in the near term.
AI summary
What happened, with direct paths to the underlying reporting
Sensus reported Q2 2026 revenue of $2.3M, down from $7.3M in 2025, as eight units’ revenue shifted to Q3 due to financing timing. Management cites CPT-code adoption and a CMS proposed 26% hospital-based SRT code increase as key tailwinds, with APAC expansion and 153% YoY website growth signaling stronger demand and potential profitability in H2 2026.
Q2 2026 revenue was $2.3M; units sold 11 vs 19 in 2025.
Eight units' revenue moved to Q3 due to financing timing.
CMS proposals a 26% hospital-based SRT code increase; reimbursement outlook improves.
APAC expansion (Australia, New Zealand) and 153% YoY website growth signal demand.
Net loss $8.7M; gross margin 34.8%; cash $15.2M; no revolver borrowings.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
